SAVE is an international study, attempting to discover if the use of CPAP can reduce the risk of heart attack, stroke or heart failure in patients with OSA. Screening and recruitment for SAVE is now complete and follow up visits will be continuing until the end of 2015.
Those who met the entry requirements and agreed to take part in SAVE were screened for OSA using a simple overnight diagnostic device in their own home. If the results of this test indicate you have OSA, they were invited to enrol into the main phase of the study.
Participants who then consented to continue into the study's main phase, were randomly allocated (like the toss of a coin) to either receive treatment with CPAP, or to continue with usual medical care. In this main phase, the effects of CPAP on cardiovascular disease will be evaluated.
Participants will then be followed up by hospital staff for 2-7 years until the end of 2015, and their health and the impact of the OSA treatment will be evaluated. The results may lead to a new medical approach to the treatment of heart attacks and strokes.